Holen Sie sich die Stockscreener-App
75.23
0.38%
0.1916
Schlusskurs vom Vortag:
$75.04
Offen:
$74.51
24-Stunden-Volumen:
163.74K
Relative Volume:
0.10
Marktkapitalisierung:
$10.09B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$586.71M
KGV:
17.52
EPS:
4.2937
Netto-Cashflow:
$605.57M
1W Leistung:
-6.61%
1M Leistung:
-8.53%
6M Leistung:
-14.22%
1J Leistung:
+27.50%
1-Tages-Spanne:
$74.01
$75.51
1-Wochen-Bereich:
$74.01
$81.54
52-Wochen-Spanne:
$54.15
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Firmenname
Globus Medical Inc
Sektor
Branche
Telefon
610-930-1800
Adresse
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
75.19 | 10.08B | 3.10B | 586.71M | 605.57M | 4.2937 |
ABT
Abbott Laboratories
|
106.17 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.84 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.97 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.62 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.51 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Needham | Hold → Buy |
| 2026-01-27 | Eingeleitet | TD Cowen | Buy |
| 2025-11-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-07 | Hochstufung | Truist | Hold → Buy |
| 2025-10-28 | Fortgesetzt | Stifel | Hold |
| 2025-05-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-01-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-08-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-09-19 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-02-13 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-02-10 | Herabstufung | Loop Capital | Buy → Hold |
| 2023-02-10 | Herabstufung | Needham | Buy → Hold |
| 2023-02-10 | Herabstufung | Truist | Buy → Hold |
| 2023-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-12-13 | Hochstufung | BofA Securities | Underperform → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-29 | Eingeleitet | Loop Capital | Buy |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2020-12-08 | Eingeleitet | Citigroup | Buy |
| 2020-10-20 | Eingeleitet | Stifel | Hold |
| 2020-08-06 | Bestätigt | Needham | Buy |
| 2020-08-06 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-21 | Eingeleitet | Northland Capital | Market Perform |
| 2020-07-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-05-08 | Bestätigt | Needham | Buy |
| 2020-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-08-02 | Bestätigt | Needham | Buy |
| 2019-05-24 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-05-03 | Bestätigt | Needham | Buy |
| 2019-02-28 | Hochstufung | UBS | Neutral → Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-06-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-03 | Bestätigt | Needham | Buy |
| 2018-04-04 | Hochstufung | Needham | Hold → Buy |
Alle ansehen
Globus Medical Inc Aktie (GMED) Neueste Nachrichten
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - Zacks Investment Research
Globus Medical Clears Excelsius3D for European Sales - MyChesCo
Globus Medical, Inc. (GMED) Stock Analysis: Healthcare Innovator with a 31.86% Upside Potential - DirectorsTalk Interviews
Globus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging System - Yahoo Finance
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union - Orthopedics This Week
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System - Ortho Spine News
Globus Medical’s Excelsius3D imaging system receives CE mark - Yahoo Finance
Globus Medical receives CE mark for Excelsius3D imaging system By Investing.com - Investing.com South Africa
Globus Medical Inc (GMED) Stock Down 3.1% -- Now Undervalued? GF Score: 94/100 - GuruFocus
Globus Medical’s $840.5 Million War Chest — Robotics, Innovation & Expansion Converge! - Smartkarma
Globus Medical stock rises on EU approval for imaging system By Investing.com - Investing.com South Africa
Globus Medical Announces CE Mark for Excelsius3D Imaging System - Investing News Network
Globus Medical stock rises on EU approval for imaging system - Investing.com
Globus Medical Slides 3.1% Despite New Product Milestone as Investors Weigh Recent Growth Questions - Quiver Quantitative
Globus Medical Wins EU, UK Approval to Market Excelsius3D Imaging Platform - marketscreener.com
Globus Medical receives CE mark for Excelsius3D imaging system - Investing.com
Audubon’s Globus Medical Acquires Duke Spinout Higgs Boson Health - BioBuzz
3 Reasons Growth Investors Will Love Globus Medical (GMED) - Eastern Progress
Globus Medical Buys Higgs Boson to Expand Digital Care - MyChesCo
Globus Medical, Inc. (GMED) Investor Outlook: Analyzing a 24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
M&A: Globus Medical Acquires Duke Incubator Higgs Boson Health to Expand Surgical Intelligence - HIT Consultant
BMO Capital Maintains Globus Medical(GMED.US) With Buy Rating, Maintains Target Price $94 - Moomoo
Wall Street Analysts Believe Globus Medical (GMED) Could Rally 25.03%: Here's is How to Trade - Yahoo Finance
Is Globus Medical (GMED) A Bargain On Its Robotics And Margin Growth Story? - Yahoo Finance
Globus Medical acquires digital health firm Higgs Boson By Investing.com - Investing.com Nigeria
Globus Medical Acquires Higgs Boson Health to Expand Digital Healthcare and Surgical Intelligence Ecosystem - Quiver Quantitative
Globus Medical announces AI acquisition with a 95% good-outcomes goal at 10 years - Stock Titan
Globus Medical acquires digital health firm Higgs Boson - Investing.com
Globus Medical, Inc. agreed to acquire Higgs Boson, Inc. - marketscreener.com
Globus Medical Inc (GMED) Stock Down 3.3% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Globus Medical (GMED) Could Be 17% Undervalued On Its Robotics Growth Narrative - Sahm
Globus Medical (NYSE:GMED): A Decent Value Stock With Solid Fundamentals - ChartMill
Globus Medical (GMED) Stock Could Be Undervalued Following Margin Gains Update - Yahoo Finance
Globus Medical Inc (GMED) Stock Down 3.0% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Globus Medical Director Stephen T. Zarrilli Executes Stock Options and Sells Shares on August 18, 2026 - Kalkine Media
Globus Medical Director Sold Shares Worth Over $2.1M - TradingView
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares - Stock Titan
Globus Medical: The Dip Makes It Cheaper, Not Different (NYSE:GMED) - Seeking Alpha
Globus Medical: 7 Quarters Of Margin Expansion, Priced For None (NYSE:GMED) - Seeking Alpha
Globus Medical (NYSE: GMED) insider plans $2.2M sale - Stock Titan
Looking for a Growth Stock? 3 Reasons Why Globus Medical (GMED) is a Solid Choice - qz.com
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now - Yahoo Finance
Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)? - Sahm
Globus Medical (GMED) Stock Analysis: Navigating a 20% Potential Upside with Healthcare Innovation - DirectorsTalk Interviews
Assenagon Asset Management S.A. Sells 127,216 Shares of Globus Medical, Inc. $GMED - MarketBeat
Globus Medical (GMED) Institutional Ownership 2026 - MarketBeat
Globus Medical Inc (GMED) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Trim Growth Views - Yahoo Finance
Is Globus Medical (GMED) A Bargain On Its Zacks Upgrade And Reaffirmed Guidance? - Yahoo Finance
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo Finance
Globus Medical (NYSE:GMED) Upgraded at Zacks Research - MarketBeat
Finanzdaten der Globus Medical Inc-Aktie (GMED)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):